This article is available online at http://www.jlr.org populations. NAFLD is the hepatic manifestation of metabolic syndrome and is associated with a cluster of metabolic risk factors including obesity, dyslipidemia, type 2 diabetes, and hypertension ( 1 ). The prevalence of NAFLD is ف 30% in US adults but is as high as 90-95% in obese individuals and у 60% in type 2 diabetic subjects ( 2 ). NAFLD is viewed as a pathological spectrum with benign fatty liver at one end and nonalcoholic steatohepatitis (NASH; infl ammation, oxidative stress, hepatic damage, and fi brosis) at the other end ( 1 ). Thirty to 40% of individuals with simple fatty liver develop NASH, which can progress to cirrhosis, a risk factor for hepatic cancer ( 3 ).NAFLD involves excessive neutral lipid storage in the liver as TG, cholesteryl ester, and diacylglycerol (DAG) ( 4-6 ). NEFAs used for TG synthesis are derived from multiple sources including those mobilized from adipose tissue, Abstract Nonalcoholic fatty liver disease is a major public health concern in the obese and type 2 diabetic populations. Nonalcoholic fatty liver disease (NAFLD) is a signifi cant public health concern for the obese and type 2 diabetic